Convatec Group Plc
United Kingdom · GB00BD3VFW73 · reports in USD · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +6.6% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 12% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 40% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | $2.1B | $2.1B | $2.3B | $2.4B |
| Operating profit | $207M | $263M | $325M | $316M |
| Earnings per share | $0.03 | $0.06 | $0.09 | $0.09 |
| Cash from operations | $282M | $367M | $397M | $470M |
| Cash | $144M | $98M | $65M | $68M |
| Total assets | $3.6B | $3.7B | $3.5B | $3.8B |
| Equity | $1.6B | $1.7B | $1.7B | $1.5B |
What they do
In the company's own words, from the annual report.
Convatec is deeply committed to the people we serve – patients living with chronic conditions, their families and caregivers, and the healthcare professionals who support themSince 1978, we have supported people living with chronic conditions. Convatec has leading positions in Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.